Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Weimar

Showing results (401-410 of 436) with videos related to

Pageof 44
Sort By:
Clinical and Experimental Immunology|July 28, 2005
The direct and indirect allogeneic presentation pathway during acute rejection after human cardiac transplantationN M van Besouw, J M Zuijderwijk, L M B Vaessen, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 30, 2012
A realistic proposal--incentives may increase donation--we need trials now!A Matas, J A E Ambagtsheer, R Gaston, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 19, 2008
Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokineticsE van Gurp, W Weimar, R Gaston, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|September 1, 2004
The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapyD A Hesselink, T van Dam, H J Metselaar, et al.
Transplantation Proceedings|February 1, 1987
Circadian variation of heart rate but not of blood pressure after heart transplantationG J Wenting, A H vd Meiracker, M L Simoons, et al.
Transplantation|September 26, 2001
Pretransplant donor-specific helper T cell reactivity as a tool for tailoring the individual need for immunosuppressionB J van der Mast, N M van Besouw, P de Kuiper, et al.
Clinical Transplantation|October 31, 2001
Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-beta 1 type I receptor expressionC C Baan, I C van Riemsdijk-van Overbeeke, A H Balk, et al.
The New England Journal of Medicine|September 14, 1989
Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allograftsE L Lagaaij, I P Hennemann, M Ruigrok, et al.
Patient Education and Counseling|December 20, 2015
Kidney transplant patients' attitudes towards self-management support: A Q-methodological studyJ W Grijpma, M Tielen, A L van Staa, et al.
The New England Journal of Medicine|December 8, 1988
Auxiliary partial liver transplantation for end-stage chronic liver diseaseO T Terpstra, S W Schalm, W Weimar, et al.
Pageof 44

Showing results (401-410 of 436) with videos related to

Sort By:
Pageof 44
Clinical and Experimental Immunology|July 28, 2005
The direct and indirect allogeneic presentation pathway during acute rejection after human cardiac transplantationN M van Besouw, J M Zuijderwijk, L M B Vaessen, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 30, 2012
A realistic proposal--incentives may increase donation--we need trials now!A Matas, J A E Ambagtsheer, R Gaston, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 19, 2008
Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokineticsE van Gurp, W Weimar, R Gaston, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|September 1, 2004
The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapyD A Hesselink, T van Dam, H J Metselaar, et al.
Transplantation Proceedings|February 1, 1987
Circadian variation of heart rate but not of blood pressure after heart transplantationG J Wenting, A H vd Meiracker, M L Simoons, et al.
Transplantation|September 26, 2001
Pretransplant donor-specific helper T cell reactivity as a tool for tailoring the individual need for immunosuppressionB J van der Mast, N M van Besouw, P de Kuiper, et al.
Clinical Transplantation|October 31, 2001
Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-beta 1 type I receptor expressionC C Baan, I C van Riemsdijk-van Overbeeke, A H Balk, et al.
The New England Journal of Medicine|September 14, 1989
Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allograftsE L Lagaaij, I P Hennemann, M Ruigrok, et al.
Patient Education and Counseling|December 20, 2015
Kidney transplant patients' attitudes towards self-management support: A Q-methodological studyJ W Grijpma, M Tielen, A L van Staa, et al.
The New England Journal of Medicine|December 8, 1988
Auxiliary partial liver transplantation for end-stage chronic liver diseaseO T Terpstra, S W Schalm, W Weimar, et al.
Pageof 44